




Olink — Scalable, multiplexed biomarkers

Rules-Based Medicine — a leader in testing soluble proteins for 25 years — performs Olink testing to support efficiency and precision in your clinical trials.


Olink's proximity extension assay (PEA[®]) technology delivers the throughput you need without compromising specificity or scalability.

Whether you need a small panel of focused biomarkers or a comprehensive exploratory assessment, RBM has an Olink option to meet your needs.




Proximity extension assay (PEA[®]) technology

Immuno-reaction




The Olink PEA technology employs a dual-recognition approach using antibody pairs labeled with complementary DNA oligonucleotides.

Extension and pre-amplification



When the antibody pair binds to the target protein, the oligonucleotides are brought into proximity and hybridize, creating a unique DNA barcode for each protein.

Amplification and detection



This DNA barcode is then extended and amplified by polymerase chain reaction (PCR) and measured by quantitative PCR (qPCR) or next-generation sequencing (NGS).

Olink is well suited to:



Evaluate therapeutic effects

Accurately measure at baseline and after treatment to understand the dynamic changes associated with a therapeutic candidate.



Understand disease onset and mechanism of action

Certain biomarkers are present years before diagnosis. Olink can help identify the relevant proteomic changes.



Develop biomarker signatures

Explore HT measures thousands of proteins at once. Longitudinal studies can help you understand proteomic profiles for different diseases.



Identify drug targets

Disease-specific proteomic signatures can help identify potential drug targets.



Available Olink products



Explore HT

5400+ proteins from a single sample

- High-throughput, scalable biomarker discovery and analysis
- Integrates with other omics data for a comprehensive picture
- Useful for identifying disease targets, pharmacokinetics, longitudinal and population-based studies

Target 48

Carefully selected biomarkers for a comprehensive view:

- Cytokine
- Immune Surveillance

Target 96

Biomarkers targeting specific therapeutic areas:

- Cardiovascular II, Cardiovascular III
- Oncology II, Immuno-Oncology, Immune Response
- Neurology, Neuro Exploratory
- Inflammation, Metabolism, Mouse Exploratory



Ask your RBM representative about Reveal, Flex and Focus.

Choose RBM for exceptional science and service excellence



Service excellence

- RBM is an Olink service provider
- Responsive client services team
- My Green Lab® – bronze certification
- Hands-on project managers who have experience working in the lab
- 20+ years of expertise in delivering high-quality results on a timeline that meets your requirements.



Exceptional science

- Dual-recognition approach uses antibody pairs labeled with DNA oligonucleotides
- Hybridization creates a unique barcode that is amplified using PCR
- Readouts by qPCR or NGS based on platform



Meaningful insights

Disease-specific insights:

- Oncology
- Inflammation/Immunology
- Cardiovascular

Broad biosignatures (Explore HT)

- Deeper understanding of biological pathways and multi-omics interactions
- Scalable without compromising quality

Contact us

Toll free: +1 866.726.6277

Direct: +1 512.835.8026

Email: rbm_clientservices@iqvia.com

Website: rbm.iqvia.com